Rigel Pharmaceuticals Inc. (RIGL) News Headlines

▮ More

Date

Headline

9/1/2021 8:55:56 AM Rigel's Phase 2 Data Of Fostamatinib In COVID-19 Patients Published In Clinical Infectious Diseases

9/1/2021 7:36:50 AM Rigel Pharma : Phase 2 Trial Data Show Fostamatinib Improves Clinical Outcomes In Hospitalized COVID-19 Patients

8/13/2021 7:54:15 AM Rigel : FDA Didn't Issue EUA For Fostamatinib For Treatment Of COVID-19 In Hospitalized Adults

8/3/2021 4:12:36 PM EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q2 Earnings Report

8/3/2021 4:06:30 PM Rigel Pharma Q2 Loss/share $0.08 Vs. Loss $0.10 Year Ago

8/3/2021 3:00:17 PM Rigel Pharmaceuticals Q2 21 Earnings Conference Call At 4:30 PM ET

7/14/2021 7:31:53 AM Rigel Pharma Presents New TAVALISSE Data Analyses At ISTH 2021 Congress

6/29/2021 7:54:32 AM Rigel's Fostamatinib Selected For NIH ACTIV-4 COVID-19 Clinical Trial

5/14/2021 7:31:06 AM Rigel Pharmaceuticals Appoints Alison Hannah To Its Board

5/5/2021 4:10:39 PM Rigel Pharmaceuticals Inc. Bottom Line Rises In Q1

5/5/2021 4:06:14 PM Rigel Reports Q1 EPS Of $0.22 Vs. $0.13 Last Year

5/5/2021 3:03:14 PM Rigel Pharmaceuticals Q1 21 Earnings Conference Call At 4:30 PM ET

4/13/2021 7:18:47 AM Rigel Pharma Says Phase 2 Trial Of Fostamatinib For COVID-19 Met Primary Endpoint Of Safety

4/13/2021 7:02:23 AM Rigel Reports Positive Topline Results From Phase 2 Clinical Trial To Evaluate Safety Of Fostamatinib

4/7/2021 7:31:13 AM Rigel Announces Closing Of License Agreement With Lilly

3/11/2021 7:45:15 AM Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients

3/11/2021 7:36:55 AM Rigel Completes Patient Enrollment For NIH/NHLBI-Sponsored Phase 2 Trial Of Fostamatinib In COVID-19 Patients

3/2/2021 4:04:20 PM EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q4 Earnings Report

3/2/2021 4:02:42 PM Rigel Pharmaceuticals Q4 Loss/share $0.11 Vs. Loss $0.10 Year Ago

3/2/2021 6:03:58 AM Rigel Pharmaceuticals Q4 20 Earnings Conference Call At 4:30 PM ET